COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents

COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents

Summary: Background: Nursing home (NH) residents have borne a disproportionate share of SARS-CoV-2 morbidity and mortality. Vaccines have limited hospitalisation and death from earlier variants in this vulnerable population. With the rise of Omicron and future variants, it is vital to sustain and b...

Full description

Bibliographic Details
Main Authors:	David H. Canaday, Oladayo A. Oyebanji, Elizabeth White, Debbie Keresztesy, Michael Payne, Dennis Wilk, Lenore Carias, Htin Aung, Kerri St. Denis, Maegan L. Sheehan, Sarah D. Berry, Cheryl M. Cameron, Mark J. Cameron, Brigid M. Wilson, Alejandro B. Balazs, Christopher L. King, Stefan Gravenstein
Format:	Article
Language:	English
Published:	Elsevier 2022-06-01
Series:	EBioMedicine
Subjects:	COVID-19 Vaccination Booster Omicron Geriatrics Long-term care
Online Access:	http://www.sciencedirect.com/science/article/pii/S235239642200247X

Similar Items

Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations
by: Donald J. Alcendor, et al.
Published: (2023-04-01)

The importance of booster vaccination in the context of Omicron wave
by: Zichun Wei, et al.
Published: (2022-09-01)

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
by: Dorota Zarębska-Michaluk, et al.
Published: (2022-07-01)

Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants
by: Liqiu Jia, et al.
Published: (2022-07-01)

Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
by: Vivek P. Chavda, et al.
Published: (2022-02-01)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
by: Jianyang Liu, et al.
Published: (2023-12-01)

Effectiveness of COVID-19 Vaccine Booster Shot Compared with Non-Booster: A Meta-Analysis
by: Yajuan Zhu, et al.
Published: (2022-08-01)

Effect of second booster vaccination on clinical outcomes of Omicron-variant breakthrough infection: A propensity score matching cohort study
by: Denggao Peng, et al.
Published: (2024-01-01)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
by: Tao Li, et al.
Published: (2023-12-01)

Interactive effect of booster vaccination and vitamin D status on antibody production of Omicron variant‐infected adults: A real‐world cohort study
by: Denggao Peng, et al.
Published: (2023-10-01)

Immunogenicity against the Omicron Variant after mRNA-Based COVID-19 Booster Vaccination in Medical Students Who Received Two Primary Doses of the mRNA-1273 Vaccine
by: Hyemin Chung, et al.
Published: (2022-12-01)

Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS‐CoV‐2 Omicron BA.1 variant
by: Zhongcheng Zhou, et al.
Published: (2022-06-01)

Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron
by: Daniela Bottero, et al.
Published: (2023-11-01)

Inactivated COVID-19 vaccine booster dose shortened the viral shedding time of patients infected with the Omicron variant BA.2
by: Jun Wu, et al.
Published: (2023-06-01)

mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
by: Biyan Zhang, et al.
Published: (2022-06-01)

Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study
by: Xiaofeng He, et al.
Published: (2023-10-01)

The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis
by: Yuntao Zou, et al.
Published: (2022-07-01)

Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients
by: Lei Zhang, et al.
Published: (2023-01-01)

Real-world effectiveness of full and booster mRNA vaccination for coronavirus disease 2019 against disease severity during the delta- and omicron-dominant phases: A propensity score-matched cohort study using the nationwide registry data in Japan
by: Tetsuya Suzuki, et al.
Published: (2024-02-01)

Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
by: Suvichada Assawakosri, et al.
Published: (2022-09-01)

Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
by: Barbara Grüne, et al.
Published: (2022-06-01)

A New Chapter in the COVID-19 Pandemic: the Characteristics of Omicron Variant and A New Step for Scientific Epidemic Prevention and Control
by: LI Yi, et al.
Published: (2023-01-01)

Selective adaptation of SARS-CoV-2 Omicron under booster vaccine pressure: a multicentre observational studyResearch in context
by: Ralf Duerr, et al.
Published: (2023-11-01)

Effectiveness of mRNA Vaccine Booster against SARS-CoV-2 Infection and COVID-19 in the Adult Population during the First Three Months of the Omicron Wave in Sicily
by: Giuseppe Vella, et al.
Published: (2023-01-01)

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
by: Shohei Yamamoto, et al.
Published: (2023-05-01)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
by: Joy-Yan Lam, et al.
Published: (2022-12-01)

Modelling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Thailand
by: Karan Thakkar, et al.
Published: (2023-12-01)

Modeling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Malaysia
by: Karan Thakkar, et al.
Published: (2023-12-01)

Combined Impact of Omicron Vaccination and Environmental Risk Exposure: A Thailand Case Study
by: Weerawat Ounsaneha, et al.
Published: (2023-01-01)

Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
by: Suvichada Assawakosri, et al.
Published: (2024-01-01)

Second booster dose improves antibody neutralization against BA.1, BA.5 and BQ.1.1 in individuals previously immunized with CoronaVac plus BNT162B2 booster protocol
by: Guilherme R. F. Campos, et al.
Published: (2024-04-01)

Immune Persistence against SARS-CoV-2 after Primary and Booster Immunization in Humans: A Large-Scale Prospective Cohort Study
by: Juan Li, et al.
Published: (2022-10-01)

Real-World Effectiveness of a Booster Dose of the COVID-19 Vaccines among Japanese University Students
by: Shunsuke Miyauchi, et al.
Published: (2022-08-01)

Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy
by: Yingyu He, et al.
Published: (2023-05-01)

Strategies and safety considerations of booster vaccination in COVID-19
by: Hanyan Meng, et al.
Published: (2022-06-01)

Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update
by: Ranjan K. Mohapatra, et al.
Published: (2022-11-01)

Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations
by: Thomas Perkmann, et al.
Published: (2023-08-01)

Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies
by: Shangchen Song, et al.
Published: (2023-06-01)

Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine
by: Kerri Basile, et al.
Published: (2022-09-01)

Public health impact of UK COVID-19 booster vaccination programs during Omicron predominance
by: Diana Mendes, et al.
Published: (2023-12-01)